Number of Panel Genes2

This test is designed to detect carriers of spinal muscular atrophy. Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder characterized by muscle weakness and atrophy resulting from progressive loss of motor neurons in the spinal cord and brain stem (MIM 253300, 253550, 253400, 271150). The age of onset and severity of the disorder are highly variable.

This test is designed to detect carriers of spinal muscular atrophy. Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder characterized by muscle weakness and atrophy resulting from progressive loss of motor neurons in the spinal cord and brain stem (MIM 253300, 253550, 253400, 271150). The age of onset and severity of the disorder are highly variable. The more common early onset forms, when treated with only supportive care, typically result in death due to respiratory failure by the age of two. Later onset forms are associated with a slower decline in motor function and, in some cases, normal life expectancy. Targeted therapies have recently become available and will likely improve the clinical course of this disorder. In most affected individuals, SMA is due to homozygous loss (0 copies) of the SMN1 gene (NM_022874). Individuals with milder presentations often have an increase in the number of copies (>2 copies) of the highly homologous SMN2 gene (NM_022876). Individuals with one copy of SMN1 are carriers of SMA and are at risk of having a child with SMA. Individuals with two or more copies of SMN1 generally have a low carrier risk. Most individuals with two copies of SMN1 have one copy on each chromosome [1+1]; however, some individuals have two copies of SMN1 on one chromosome and zero copies on the other chromosome [2+0]. Individuals with a [2+0] configuration are known as silent carriers and are at risk of having a child with SMA. The presence of the SMN1 c.*3+80T>G SNP correlates in certain populations with increased risk of being a silent carrier of SMA (g.27134T>G, see Luo: PMID 23788250). If both reproductive partners are SMA carriers/silent carriers, the risk for SMA in their children is 25%. SMA is the most common genetic cause of infant death and the American College of Obstetrics and Gynecology (ACOG) recommends offering SMA carrier screening to all women who are pregnant of considering pregnancy. This test is intended for pre/post-conception carrier screening and is not intended for diagnostic testing.

Gene(s)

SMN1 SMN2

MIM

253300 253550 253400 271150

Methodology

Billing

CPT Code(s)
81329 x 1

Ordering

Test Code
6008

Additional Test Codes
Please call for pricing

Turnaround Time
Typically within 2 weeks from receipt of a sample in the laboratory.

Specimens
Whole blood: purple-top (EDTA) tube, minimum of 3 ml
Genomic DNA: minimum of 3 µg (at a concentration of at least 30 ng/µl)

Shipping
Ship all specimen types at room temperature by overnight courier. Do not freeze.

The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. HNL Lab Medicine strongly recommends confirmation of CPT codes with third-party payors and/or the AMA. We assume no responsibility for billing errors due to reliance upon CPT codes provided by HNL Lab Medicine.

News

October 28, 2022

Non-Hodgkin Lymphoma FISH Panel Now Available

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas.
Read More
October 20, 2022

Genetic testing for Familial Transthyretin Amyloidosis (TTR) NOW AVAILABLE In-House

Hereditary amyloidosis is a life-threatening disorder that can lead to peripheral neuropathy and heart failure.
Read More
August 08, 2022

Familial hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is a genetic disorder that increases the likelihood of having coronary heart disease at a younger age. Learn about how to determine if you have hypercholesterolemia and what actions you can take to create better outcomes!

Read More
April 11, 2022

Genome Sequencing: A Vital Tool Used in Identifying and Tracking New COVID-19 Variants

Genome sequencing is reading or decoding the complete genetic information i.e. “Genome” of an organism that is encrypted in the form of a very long string called DNA made up of 4 letters, A, T, G, and C. The genome of an organism essentially determines their physical characteristics and ...
Read More
March 03, 2022

The Effect of Genetics on Individual Heart Health: Early Identification of FH Variations to Optimize Treatment

Test must be ordered by a Physician.

Familial hypercholesterolemia (FH) is a genetic disorder that is characterized by abnormally high blood levels of low-density lipoprotein (LDL) cholesterol, sometimes referred to as "bad cholesterol". This condition affects an estimated 1 in 250 people, and increases the likelihood of developing cardiovascular disease. In fact, FH is estimated to be the cause of 2-3% of heart attacks in individuals younger than age 60.

Read More